TIDMPXS

RNS Number : 4315W

Provexis PLC

11 December 2019

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ('MAR'). With the publication of this announcement, this information is now considered to be in the public domain.

11 December 2019

Provexis plc

('Provexis' or the 'Company')

Placing of new ordinary shares to raise GBP0.301 million

Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow(R) heart-health functional food ingredient, is pleased to announce it has raised a gross GBP301,333 via a placing (the 'Placing'), conditional on admission to trading on AIM, of 75,333,333 new ordinary shares of 0.1p each (the 'New Provexis Shares') with new and existing investors.

The New Provexis Shares will be issued at a price of 0.40p per share (the 'Placing Price'), and rank pari passu in all respects with the existing ordinary shares of 0.1p each in Provexis. No commissions or expenses will be payable on the issue of the New Provexis Shares. The proceeds of the Placing will be used for general working capital requirements.

The Placing Price represents a discount of 11.1 per cent. to the closing mid-market price per Ordinary Share on 10 December 2019, being the latest practicable date prior to this announcement.

Application will be made to the London Stock Exchange for the New Provexis Shares to be admitted to trading on AIM. It is expected that the admission will become effective and that trading in the New Provexis Shares will commence on or around 17 December 2019 ('Admission').

Following Admission, the Company's enlarged issued share capital will comprise 2,059,321,507 ordinary shares with voting rights. The Company does not hold any shares in treasury. This figure of 2,059,321,507 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information please contact:

 
 Provexis plc                  Tel: 07490 391888 
  Ian Ford, CEO                 enquiries@provexis.com 
  Dawson Buck, Chairman 
 Allenby Capital Limited       Tel: 020 3328 5656 
  Nick Naylor / Liz Kirchner

Notes for editors

About Provexis plc

AIM-listed Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow(R) heart-health functional food ingredient.

Provexis was founded in 1999 and is headquartered in Reading, Berkshire.

Provexis shares are traded on the AIM market of the London Stock Exchange under the ticker symbol PXS.

For further information, please visit www.provexis.com and www.fruitflowplus.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

IOEEAPAEFFPNFFF

(END) Dow Jones Newswires

December 11, 2019 02:00 ET (07:00 GMT)

Provexis (LSE:PXS)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Provexis.
Provexis (LSE:PXS)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Provexis.